Compare BIO-TECHNE Corp (TECH) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Total International Stock Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $72.44 (market cap $11.36B), while Vanguard Total International Stock Index Fund ETF trades at $84.96 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 58.6× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Total International Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 64 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| TECH | VXUS | |
|---|---|---|
Market Cap | $11.36B | $665.70B |
Volume | 5,390,331 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $72.61 | $88.41 |
52-Week Low | $43.31 | $72.17 |
Typical Hold Time | 64 Days | 55 Days |
Enterprise Value | $11.39B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
VXUS trades at $84.67, down 0.13% with a bearish technical signal from moving averages and oscillators. The ETF provides diversified international stock exposure excluding U.S. markets, with recent institutional buying interest from firms like QRG Capital and Baird Financial. Support levels cluster around $83-84 while resistance sits at $85.
The outlook remains cautious given technical bearishness, though long-term diversification benefits and institutional accumulation provide support. Key risks include foreign market volatility and currency fluctuations, while the absence of U.S. exposure offers portfolio hedging advantages during domestic downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
